Trade Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in Woodlands, Texas under the name Of Lexicon Genetics, founded by co-founders Professor Alan Bradley, FRS and fellow postdoctoral Professor Bradley Arthur T. Sands. The company has used patented mouse gene-wide-ranging knockout technology in live body screening capabilities to study nearly 5,000 genes in its Genome5000 program and identified more than 100 potential therapeutic targets. Dictionary has advanced many drug candidates in human clinical trials and has a wide and varied pipeline of drug targets behind its clinical programs. The dictionary seeks to achieve drug goals in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology. candidates include clinical drugs for the company sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other digestive disorders; telotristat ethyl (LX1032) to treat symptoms associated with cancer syndrome; LX2931 is for the treatment of autoimmune diseases, such as rheumatoid arthritis.